Advertisement
Advertisement
Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EDT
After hours:
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 78.76 |
| Open | 78.93 |
| Bid | 79.77 x 900 |
| Ask | 80.34 x 1000 |
| Day's Range | 78.34 - 80.40 |
| 52 Week Range | 57.17 - 89.74 |
| Volume | |
| Avg. Volume | 6,172,168 |
| Market Cap | 99.769B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | 22.16 |
| EPS (TTM) | 3.61 |
| Earnings Date | Apr 26, 2023 - May 01, 2023 |
| Forward Dividend & Yield | 3.00 (3.78%) |
| Ex-Dividend Date | Mar 14, 2023 |
| 1y Target Est | 88.96 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
36% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for GILD
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Gilead Sciences, Inc.Analyst Report: Gilead Sciences, Inc.Gilead Sciences is a California-based biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 17,000 employees.RatingFair ValueEconomic Moat16 days agoArgus Research
- Zacks
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
- Zacks
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
Gilead Sciences (GILD) closed at $77.81 in the latest trading session, marking a -1.68% move from the prior day.
- Zacks
Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 Study
Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
